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Introduction {#sec005}
============

Kikuchi-Fujimoto disease (KFD), also known as histiocytic necrotising lymphadenitis, is a rare idiopathic inflammatory disease first described in 1972 by Kikuchi and Fujimoto et al \[[@pone.0219970.ref001], [@pone.0219970.ref002]\]. KFD mainly affects adults younger than 40 years of age and is predominant among Asian populations \[[@pone.0219970.ref003]\]. The aetiology of KFD is still unknown although various inciting agents, including the Epstein-Barr virus (EBV), human herpesvirus types 6, 7, and 8, herpes simplex virus, and HIV, have been suggested as possible causative agents \[[@pone.0219970.ref001], [@pone.0219970.ref002], [@pone.0219970.ref004]\]. KFD typically presents as persistent cervical lymphadenopathy with or without fever \[[@pone.0219970.ref005]\]. Some patients manifest non-specific systemic symptoms including night sweats, weight loss, nausea, vomiting, hepatosplenomegaly, and headache \[[@pone.0219970.ref006], [@pone.0219970.ref007]\]. The clinical characteristics of KFD can resemble those of malignant lymphoma, metastatic carcinoma, infectious lymphadenitis, systemic autoimmune diseases, and *Mycobacterium tuberculosis* infections \[[@pone.0219970.ref008]--[@pone.0219970.ref010]\]. The overall prognosis of KFD is favourable with a benign, self-limiting course. Although there is no specific treatment for KFD, supportive management with analgesics and antipyretics is usually adequate, leading to spontaneous resolution in several months \[[@pone.0219970.ref006]\].

In KFD cases with severe clinical presentations, few case reports described co-existence of hemophagocytic lymphohistiocytosis (HLH) \[[@pone.0219970.ref011]--[@pone.0219970.ref018]\]. HLH is a syndrome of excessive proinflammatory cytokine production due to uncontrolled expansion of T lymphocytes and macrophages, which is characterised by hemophagocytosis, intractable fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, and hypofibrinogenemia \[[@pone.0219970.ref019], [@pone.0219970.ref020]\]. Although primary HLH is associated with genetic defects in the perforin-mediated cytolytic pathway, macrophage activation syndrome (MAS) is considered to be a secondary form of HLH associated with malignancy, infection, and autoimmune diseases \[[@pone.0219970.ref021]\]. Because viral infections such as EBV are known to cause HLH by triggering uncontrolled lymphoproliferation \[[@pone.0219970.ref022]\], there is a concern that KFD can be associated with MAS. While MAS is a potentially life-threatening condition that requires early detection, MAS-specific diagnostic criteria have not yet been fully established. Recently, new classification criteria for MAS were developed by a collaboration of international study groups and were validated in patients with systemic juvenile idiopathic arthritis (sJIA) with excellent specificity \[[@pone.0219970.ref023], [@pone.0219970.ref024]\]. We previously demonstrated that these criteria were also useful for the identification of patients with MAS in adult-onset Still's disease (AOSD) and systemic lupus erythematosus (SLE) to predict poor hospitalisation outcomes \[[@pone.0219970.ref025], [@pone.0219970.ref026]\].

Although MAS may follow a severe and fatal course, the incidence and clinical characteristics of MAS-complicated KFD are still not well understood. In our study, we aimed to evaluate the impact of MAS on the clinical features of KFD and to compare the clinical and laboratory features of patients with MAS complicating KFD, AOSD, and SLE.

Material and methods {#sec006}
====================

Patient selection and study design {#sec007}
----------------------------------

We retrospectively reviewed the clinical and laboratory data of patients with a diagnosis of KFD between November 2005 and April 2017 in two tertiary hospitals in the Yonsei University Health System located in Shinchon and Gangnam district of Seoul, Korea. The inclusion criteria were as follows: (i) patients who were admitted with fever; (ii) patients with diagnosis of KFD that was confirmed pathologically; (iii) patients with ferritin level assessment; (iv) patients without concurrent autoimmune disease/infection. Finally, 78 patients were included in this study. The flowchart for patient selection is shown in [S1 Fig](#pone.0219970.s001){ref-type="supplementary-material"}. The clinical and laboratory data of patients with MAS in AOSD and SLE according to the 2016 classification criteria were obtained using a pre-existing dataset used in a previous study \[[@pone.0219970.ref025], [@pone.0219970.ref026]\], and all data were fully anonymized for analysis. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Severance Hospital (IRB approval number 4-2018-0624). The requirement to obtain informed consent was waived because of the retrospective nature of the study.

Definition of patients with MAS according to the 2016 classification criteria {#sec008}
-----------------------------------------------------------------------------

According to the 2016 EULAR/ACR/PRINTO classification criteria for MAS \[[@pone.0219970.ref023], [@pone.0219970.ref024]\], we classified patients as having MAS when they presented with fever, a ferritin level of ≥684 ng/mL, and fulfilled more than 2 of the following 4 criteria: platelet count ≤181,000/mL, aspartate aminotransferase (AST) level \>48 units/L, triglyceride level \>156 mg/dL, and fibrinogen level ≤360 mg/dL. In addition, patients with MAS were divided into two groups: patients having MAS on admission and those who developed MAS after admission.

Collection of clinical and laboratory variables {#sec009}
-----------------------------------------------

The clinical data collected included age, sex, length of hospital stay, in-hospital mortality, intensive care unit admission, and treatment. Poor hospitalisation outcomes were defined as intensive care unit admission or in-hospital mortality. The clinical manifestations of KFD included the presence of hepatomegaly, splenomegaly, skin rash, and joint pain. Baseline laboratory variables included white blood cells, neutrophils, lymphocyte and platelet counts, erythrocyte sedimentation rate, and levels of haemoglobin, C-reactive protein (CRP), creatinine, AST, alanine aminotransferase (ALT), albumin, ferritin, lactate dehydrogenase (LDH), fibrinogen, and triglycerides. As fibrinogen and triglyceride levels were not measured regularly, the levels obtained within 3 days of the date of laboratory data selection were included in the analysis.

Calculation of the hemophagocytic syndrome score (HScore) and patients fulfilling the HLH-2004 criteria {#sec010}
-------------------------------------------------------------------------------------------------------

The HScore was developed to evaluate individual risk for the presence of hemophagocytic syndrome \[[@pone.0219970.ref027]\] and is also useful to identify the risk of having reactive hemophagocytic syndrome in patients with rheumatic diseases \[[@pone.0219970.ref028]\]. The HScore and the probability of having hemophagocytic syndrome were calculated using an online calculator (saintantoine.aphp.fr/score). Furthermore, the proportion of patients fulfilling the HLH-2004 criteria was estimated as previously described \[[@pone.0219970.ref029]\].

Statistical analysis {#sec011}
--------------------

Continuous variables were presented as medians with interquartile ranges (IQR), and categorical variables were presented as frequencies and percentages. Continuous variables were compared using the Kruskal--Wallis test or Mann--Whitney U test, and categorical variables were compared using the chi-square or Fisher's exact test, as appropriate. Kaplan-Meier analysis and the log-rank test were used to compare the survival probability among the groups. All statistical analyses were performed using MedCalc statistical software version 18.6 (MedCalc Software, Ostend, Belgium) or GraphPad Prism software version 5.0 (GraphPad Software, San Diego, California, USA). In all statistical analyses, a two-tailed p\<0.05 was considered statistically significant.

Results {#sec012}
=======

Baseline characteristics of patients with and without MAS {#sec013}
---------------------------------------------------------

Of the 78 patients included in the study, 24 (30.8%) were classified as having MAS during admission ([Table 1](#pone.0219970.t001){ref-type="table"}). Among the 24 patients, 20 (83.3%) had MAS on admission, and 4 (16.7%) developed MAS after admission. Although the clinical manifestations were not different between patients with and without MAS, patients with MAS were older and had a longer hospital stays, and the proportion of patients with poor hospitalisation outcomes was significantly higher in patients with MAS (29.2% vs. 0.0%, p\<0.001). In addition, the median HScore (97.0 \[IQR 68.0--128.5\] vs 49.0 \[IQR 33.0--72.0\]) and the probability of having hemophagocytic syndrome were higher in patients with MAS than in patients without MAS (all p\<0.001) ([Fig 1A and 1B](#pone.0219970.g001){ref-type="fig"}). Furthermore, the proportion of patients requiring glucocorticoid treatment was significantly higher in patients with MAS (66.7% vs 40.7%, p = 0.036). Regarding laboratory findings, patients with MAS had higher CRP, ALT, and LDH levels and a lower lymphocyte count and albumin levels than those without MAS. Among the laboratory variables selected for MAS classification, higher AST and ferritin levels and lower platelet counts were observed in patients with MAS; however, the differences between triglyceride and fibrinogen levels were not significant ([Table 2](#pone.0219970.t002){ref-type="table"}). Of the 19/78 (24.4%) patients who had undergone a bone marrow study, only 2 patients in the MAS group were found to have hemophagocytosis.

10.1371/journal.pone.0219970.t001

###### Clinical characteristics of patients with KFD with and without MAS.

![](pone.0219970.t001){#pone.0219970.t001g}

                                       Without MAS (n = 54)   With MAS (n = 24)   p-value
  ------------------------------------ ---------------------- ------------------- ---------
  **Demographic data**                                                            
   Age, years                          26.0 (21.0--35.0)      40.0 (32.5--55.0)   \<0.001
   Female sex                          37 (68.5)              15 (62.5)           0.605
  **Clinical manifestations**                                                     
   Hepatomegaly                        6 (11.1)               0 (0.0)             0.169
   Splenomegaly                        12 (22.2)              7 (29.2)            0.512
   Skin rash                           8 (14.9)               7 (29.2)            0.140
   Joint pain                          1 (1.9)                3 (12.5)            0.084
  **Treatment**                                                                   
   Glucocorticoid treatment            22 (40.7)              16 (66.7)           0.036
   Immunosuppressive treatment         1 (1.9)                3 (12.5)            0.084
    Hydroxychloroquine                 1 (1.9)                2 (8.3)             
    Cyclosporine                       0 (0.0)                1 (4.2)             
  **Clinical course**                                                             
   Length of stay in hospital (days)   8.5 (6.0--11.0)        12.5 (10.5--32.0)   \<0.001
   In-hospital mortality               0 (0.0)                5 (20.8)            0.002
   Intensive unit care                 0 (0.0)                7 (29.2)            \<0.001

Data expressed as median (interquartile range) or n (%). KFD, Kikuchi-Fujimoto disease; MAS, macrophage activation syndrome.

10.1371/journal.pone.0219970.t002

###### Comparison of baseline laboratory findings of patients with and without MAS.

![](pone.0219970.t002){#pone.0219970.t002g}

  Variable                                                               Without MAS (n = 54)      With MAS (n = 24)         p-value
  ---------------------------------------------------------------------- ------------------------- ------------------------- ---------
  **General laboratory variables**                                                                                           
   WBC count (/μL)                                                       3475.0 (2350.0--5000.0)   3285.0 (2335.0--5905.0)   0.996
   Hemoglobin (g/dL)                                                     12.5 (11.7--13.4)         11.7 (10.3--13.2)         0.102
   Neutrophil count (/μL)                                                1925.0 (1310.0--3050.0)   2206.5 (1375.0--4833.5)   0.378
   Lymphocyte count (/μL)                                                1045.0 (860.0--1370.0)    600.0 (490.0--940.0)      \<0.001
   ESR (mm/h)                                                            48.5 (27.0--64.0)         52.5 (39.5--72.5)         0.242
   CRP (mg/L)                                                            15.0 (7.5--37.1)          52.6 (27.7--97.1)         \<0.001
   Creatinine (mg/dL)                                                    0.7 (0.6--0.8)            0.7 (0.5--1.1)            0.349
   ALT (IU/L)                                                            21.5 (14.0--38.0)         44.5 (23.0--153.0)        0.003
   Albumin (g/dL)                                                        4.0 (3.7--4.3)            3.4 (3.1--3.7)            \<0.001
   LDH (IU/L)                                                            439.5 (291.0--611.0)      771.5 (460.0--1213.5)     0.003
  **Laboratory variables selected for MAS classification**                                                                   
   Platelet count (×1000/μL)                                             195.5 (155.0--260.0)      139.0 (94.5--184.0)       \<0.001
   AST (IU/L)                                                            29.0 (22.0--39.0)         93.5 (62.5--191.0)        \<0.001
   Ferritin (ng/mL)                                                      242.8 (112.0--405.2)      1449.7 (812.9--4463.1)    \<0.001
   Triglyceride (mg/dL)[^¶^](#t002fn002){ref-type="table-fn"}            89.0 (60.0--106.5)        133.0 (90.3--161.3)       0.076
   Fibrinogen (mg/dL)[^§^](#t002fn003){ref-type="table-fn"}              342.0 (338.0--346.0)      317.5 (227.5--401.0)      0.695
  **Bone marrow biopsy findings**[\*](#t002fn004){ref-type="table-fn"}                                                       
   Presence of hemophagocytosis                                          0/7 (0.0)                 2/12 (16.7)               0.509

Data are expressed as median (interquartile range) or n (%). MAS, macrophage activation syndrome; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; AST, aspartate aminotransferase.

^¶^Number confined to patients who underwent each test (n = 23).

^§^Number confined to patients who underwent each test (n = 10).

**\***Number confined to patients who underwent each test (n = 19).

![HScore and the probability of having hemophagocytic syndrome in patients with KFD with and without MAS.\
Comparison of HScore (A) and the probability of having hemophagocytic syndrome (B) in patients with KFD with and without MAS. HScore, hemophagocytic syndrome score; KFD, Kikuchi-Fujimoto disease; MAS, macrophage activation syndrome.](pone.0219970.g001){#pone.0219970.g001}

Clinical and laboratory findings of patients with KFD and in-hospital mortality {#sec014}
-------------------------------------------------------------------------------

As MAS in KFD is not a well-described complication, we further analysed the clinical and laboratory features of patients with KFD and in-hospital mortality ([Table 3](#pone.0219970.t003){ref-type="table"}). All patients in our study who died in the hospital had MAS, were older than 50 years of age and did not have any specific clinical manifestations. Among MAS patients with KFD (n = 24), patients aged ≥50 years had a higher mortality rate than those aged \<50 years (p = 0.003) ([Fig 2](#pone.0219970.g002){ref-type="fig"}). During the disease course, patients with MAS had increasing ferritin and AST levels, while platelet counts decreased. Most deaths occurred within 90 days, and among the five patients who died, the cause of death was multi-organ failure in 4 patients and sepsis in 1 patient ([Table 3](#pone.0219970.t003){ref-type="table"}). Hepatosplenomegaly was only observed in one patient, and no patients had co-existing comorbidities with the exception of gout in one patient.

![Comparison of the overall survival rate of patients with KFD and MAS according to age.\
In MAS patients with KFD, patients aged ≥50 years had a higher mortality rate than those aged \<50 years. KFD, Kikuchi-Fujimoto disease; MAS, macrophage activation syndrome.](pone.0219970.g002){#pone.0219970.g002}

10.1371/journal.pone.0219970.t003

###### The clinical and laboratory features of patients with KFD and in-hospital mortality.

![](pone.0219970.t003){#pone.0219970.t003g}

  Case number   Age/Sex     Main symptom                   Initial/highest ferritin level (ng/mL)   Initial/lowest platelet count (/μL)   Initial/highest AST level (IU/L)   Time to death (days)   Cause of death
  ------------- ----------- ------------------------------ ---------------------------------------- ------------------------------------- ---------------------------------- ---------------------- ---------------------
  1             68/Male     Fever                          13308.3/15000.0                          133000/27000                          178/24650                          Death in day 8         Multi-organ failure
  2             52/Female   Fever, skin rash, joint pain   14399.9/14399.9                          69000/20000                           132/134                            Death in day 11        Multi-organ failure
  3             56/Male     Fever, myalgia                 441.8/1896.6                             346000/7000                           204/8320                           Death in day 24        Sepsis
  4             61/Female   Fever, headache, nausea        15363.6/15363.6                          92000/16000                           96/394                             Death in day 32        Multi-organ failure
  5             57/Female   Sore throat, fever             528.9/38765.3                            97000/21000                           22/483                             Death in day 281       Multi-organ failure

KFD, Kikuchi-Fujimoto disease.

Clinical and laboratory features among patients with MAS in KFD, AOSD, and SLE {#sec015}
------------------------------------------------------------------------------

Next, we compared the clinical and laboratory features among patients with MAS in KFD, AOSD and SLE. Clinical and laboratory data of patients with AOSD or SLE and MAS used for comparison were obtained from the dataset of previous studies \[[@pone.0219970.ref025], [@pone.0219970.ref026]\]. Patients with AOSD were older than those with SLE, and the proportion of female patients was the lowest in patients with KFD. The presence of lymphadenopathy was significantly higher in patients with KFD than in those with AOSD or SLE ([Table 4](#pone.0219970.t004){ref-type="table"}). There were no differences in the median HScore (KFD 97.0 \[IQR 68.0--128.5\] vs AOSD 108.5 \[IQR 102.0--150.0\] vs SLE 111.0 \[IQR 76.0--137.0\], p = 0.296) or the probability of having hemophagocytic syndrome among patients with MAS in KFD, AOSD, and SLE ([S2A and S2B Fig](#pone.0219970.s002){ref-type="supplementary-material"}, p = 0.296). In addition, the number of patients fulfilling the HLH-2004 criteria was 2/24 (8.3%), 6/36 (16.7%), and 3/54 (5.6%) in KFD, AOSD, and SLE, respectively, without a statistical difference (p = 0.210). Comparison of laboratory variables between the groups showed that elevated white blood cells, neutrophils, lymphocyte count, and CRP levels were prominent in patients with AOSD, while decreased haemoglobin and albumin levels were characteristic in patients with SLE. Regarding laboratory variables selected for MAS classification, platelet count and ferritin levels were the highest in patients with AOSD, while triglyceride levels were the lowest in patients with KFD ([Table 4](#pone.0219970.t004){ref-type="table"}).

10.1371/journal.pone.0219970.t004

###### Clinical and laboratory features in patients with MAS in KFD, AOSD, and SLE.

![](pone.0219970.t004){#pone.0219970.t004g}

  Variable                                                                                     KFD (n = 24)                                                    AOSD (n = 36)                                                       SLE (n = 54)                                                  p-value
  -------------------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------- ---------
  **Demographic data**                                                                                                                                                                                                                                                                           
   Age, years                                                                                  40.0 (32.5--55.0)                                               47.5 (36.0--57.5)[\*\*](#t004fn011){ref-type="table-fn"}            37.0 (26.0--49.0)                                             0.010
   Female sex                                                                                  15 (62.5)[^b^](#t004fn005){ref-type="table-fn"}                 34 (94.4)                                                           46 (85.2)[^§^](#t004fn007){ref-type="table-fn"}               0.004
  **Clinical manifestations**                                                                                                                                                                                                                                                                    
   Hepatomegaly                                                                                0 (0.0)                                                         4 (11.1)                                                            8 (14.8)                                                      0.143
   Splenomegaly                                                                                7 (29.2)                                                        10 (27.8)                                                           16 (29.6)                                                     0.982
   Lymphadenopathy                                                                             24 (100.0)[^c^](#t004fn006){ref-type="table-fn"}                16 (44.4)                                                           29 (53.7)[^§§§^](#t004fn009){ref-type="table-fn"}             \<0.001
  **General laboratory variables**                                                                                                                                                                                                                                                               
   WBC count (/μL)                                                                             3285.0 (2335.0--5905.0)[^c^](#t004fn006){ref-type="table-fn"}   10630.0 (6915.0--6130.0)[\*\*\*](#t004fn012){ref-type="table-fn"}   2830.0 (1800.0--6210.0)                                       \<0.001
   Hemoglobin (g/dL)                                                                           11.7 (10.3--13.2)                                               10.9 (10.0--11.7)[\*\*](#t004fn011){ref-type="table-fn"}            10.1 (8.7--11.0)[^§§§^](#t004fn009){ref-type="table-fn"}      \<0.001
   Neutrophil count (/μL)                                                                      2206.5 (1375.0--4833.5)[^c^](#t004fn006){ref-type="table-fn"}   8575.0 (4780.0--14325.0)[\*\*\*](#t004fn012){ref-type="table-fn"}   2015.0 (1230.0--4320.0)                                       \<0.001
   Lymphocyte count (/μL)                                                                      600.0 (490.0--940.0)[^a^](#t004fn004){ref-type="table-fn"}      899.0 (655.0--1225.0)[\*\*\*](#t004fn012){ref-type="table-fn"}      491.4 (310.0--790.0)                                          \<0.001
   ESR (mm/h)                                                                                  52.5 (39.5--72.5)                                               61.0 (29.0--83.0)                                                   42.5 (29.0--70.0)                                             0.186
   CRP (mg/L)                                                                                  52.6 (27.7--97.1)[^a^](#t004fn004){ref-type="table-fn"}         96.4 (50.2--143.8)[\*\*\*](#t004fn012){ref-type="table-fn"}         13.5 (5.5--59.9)[^§§^](#t004fn008){ref-type="table-fn"}       \<0.001
   ALT (IU/L)                                                                                  44.5 (23.0--153.0)                                              36.0 (23.5--117.5)                                                  38.5 (24.0--68.0)                                             0.729
   Albumin (g/dL)                                                                              3.4 (3.1--3.7)                                                  3.1 (3.0--3.6)[\*](#t004fn010){ref-type="table-fn"}                 2.9 (2.4--3.3)[^§§^](#t004fn008){ref-type="table-fn"}         0.011
  **Laboratory variables selected for MAS classification**                                                                                                                                                                                                                                       
   Platelet count (×1000/μL)                                                                   139.0 (94.5--184.0)[^a^](#t004fn004){ref-type="table-fn"}       203.5 (140.0--292.0)[\*\*\*](#t004fn012){ref-type="table-fn"}       109.5 (91.0--155.0)                                           \<0.001
   AST (IU/L)                                                                                  93.5 (62.5--191.0)                                              76.5 (42.0--207.5)                                                  89.0 (50.0--183.0)                                            0.778
   Ferritin (ng/mL)                                                                            1449.7 (812.9--4463.1)[^b^](#t004fn005){ref-type="table-fn"}    6773.4 (2567.1--14610.2)[\*\*\*](#t004fn012){ref-type="table-fn"}   1483.5 (754.9--2324.7)                                        \<0.001
   Triglyceride (mg/dL)                                                                        133.0 (90.3--161.3)                                             168.0 (126.7--223.5)                                                173.0 (145.5--274.0)[^§§^](#t004fn008){ref-type="table-fn"}   0.026
   Fibrinogen (mg/dL)                                                                          317.5 (227.5--401.0)                                            302.0 (202.5--406.3)                                                253.0 (170.0--329.0)                                          0.320
  **Clinical course and treatment outcome**                                                                                                                                                                                                                                                      
   Length of stay in hospital (days)                                                           12.5 (10.5--32.0)                                               22.5 (13.0--41.5)                                                   19.0 (14.0--29.0)                                             0.257
   Glucocorticoid treatment cessation at 3 months[^†^](#t004fn002){ref-type="table-fn"}        16 (66.7)[^c^](#t004fn006){ref-type="table-fn"}                 4 (11.1)[\*](#t004fn010){ref-type="table-fn"}                       0 (0.0)[^§§§^](#t004fn009){ref-type="table-fn"}               \<0.001
   Number of Immunosuppressive treatments administered[^‡^](#t004fn003){ref-type="table-fn"}                                                                                                                                                                                                     0.018
    0--1                                                                                       24 (100.0)[^b^](#t004fn005){ref-type="table-fn"}                26 (72.2)                                                           45 (83.3)[^§^](#t004fn007){ref-type="table-fn"}               
    ≥2                                                                                         0 (0.0)                                                         10 (27.8)                                                           9 (16.7)                                                      

Data expressed as median (interquartile range) or n (%).

^†^Glucocorticoid treatment and the dosage of glucocorticoids in patients with mortality or who were lost to follow-up were counted on the last date of follow-up.

^‡^Includes treatment with disease modifying anti-rheumatic drugs, biologics, cyclosporine, and etoposide/cyclophosphamide.

^a^Difference between patients with KFD and AOSD. p \< 0.05;

^b^Difference between patients with KFD and AOSD, p \< 0.01;

^c^Difference between patients with KFD and AOSD, p \< 0.001.

^§^Difference between patients with KFD and SLE. p \< 0.05;

^§§^Difference between patients with KFD and SLE, p \< 0.01;

^§§§^Difference between patients with KFD and SLE, p \< 0.001.

\*Difference between patients with AOSD and SLE, p \< 0.05;

\*\*Difference between patients with AOSD and SLE, p \< 0.01;

\*\*\*Difference between patients with AOSD and SLE, p \< 0.001.

MAS, macrophage activation syndrome; KFD, Kikuchi-Fujimoto disease; AOSD, adult onset Still's disease; SLE, systemic lupus erythematosus; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Comparison of 90-day mortality and treatment among patients with MAS in KFD, AOSD, and SLE {#sec016}
------------------------------------------------------------------------------------------

To evaluate the prognosis of patients with MAS in different diseases, we compared the 90-day mortality among patients with MAS in KFD, AOSD, and SLE by using Kaplan-Meier analysis with the log-rank test. The number of patients with 90-day mortality in KFD, AOSD, and SLE was 4 (16.7%), 12 (33.3%), and 15 (27.8%) patients, respectively. Kaplan-Meier survival analysis showed that the survival probability among patients with MAS in KFD, AOSD, and SLE was not statistically significant (p = 0.427) ([S3 Fig](#pone.0219970.s003){ref-type="supplementary-material"}). However, the treatment for patients with KFD, AOSD, and SLE was different according to the underlying disease, and patients with KFD had a higher rate of glucocorticoid cessation after 3 months (KFD 66.7%, AOSD 11.1%, SLE 0.0%, p\<0.001) and had fewer immunosuppressive agents administered ([Table 4](#pone.0219970.t004){ref-type="table"}).

Discussion {#sec017}
==========

While KFD is pathologically characterised by a proliferation of activated cytotoxic T lymphocytes and histiocytes with central necrotic areas in lymph nodes, HLH is characterised by hemophagocytosis, engulfing erythrocytes, and leukocytes by histiocyte in the bone marrow or liver. Therefore, both KFD and HLH are associated with abnormal histiocyte activation. In addition, inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6 are also implicated in the pathogenesis of both MAS and severe cases of KFD \[[@pone.0219970.ref030], [@pone.0219970.ref031]\]. Therefore, although it is possible that HLH can be accompanied by KFD, the association between KFD and HLH is not well understood. In this study, by using the 2016 EULAR/ACR/PRINTO classification criteria, we found the incidence of MAS, a secondary form of HLH, was 30.8% in our study population of pathologically confirmed KFD. Because we included only febrile hospitalised patients with KFD, our study population might have been skewed towards those having severe laboratory abnormalities in tertiary referral centres; however, the association of MAS in KFD is an interesting finding that requires clinical attention.

KFD patients with MAS experienced longer hospital stays and worse hospitalisation outcomes, including higher rates of intensive care unit stays and in-hospital mortality than in patients without MAS. In addition, the proportion of patients with KFD requiring glucocorticoid treatment was significantly higher in patients with MAS than in patients without MAS. All 5 cases of mortality in our cohort were observed in patients with MAS who were over the age of 50. Compared to patients aged \<50 years, those aged 50 years and older had significantly higher mortality in KFD with MAS. These findings suggest that older KFD patients with MAS might be especially associated with poor prognosis.

MAS presents as non-remitting fever, generalised lymphadenopathy, hepatosplenomegaly, pancytopenia, high ferritin, and low fibrinogen levels \[[@pone.0219970.ref032]\]. Since there are no disease-specific clinical manifestations or laboratory abnormalities of MAS, and many of the symptoms resemble those of KFD itself, the clinician's suspicion is critical for the diagnosis. In addition, even though hyperferritinemia is a prerequisite in the 2016 criteria for MAS, alternative diagnoses which can be associated with elevated ferritin levels such as sepsis and catastrophic antiphospholipid syndrome should be excluded \[[@pone.0219970.ref033]\]. In our study, the difference in clinical manifestations between patients with KFD with and without MAS was not significant. On the other hand, in terms of laboratory findings, patients with KFD and MAS had higher CRP, LDH, ferritin, AST, and ALT levels and lower platelet counts, lymphocyte count, and albumin levels than patients with KFD without MAS. Importantly, in our study, a higher proportion of patients with KFD and MAS were treated with steroids than patients without MAS. Monitoring for MAS in patients with KFD could be clinically important, as patients without MAS could be treated with supportive care, while those with MAS might require steroids or additional second-line treatments such as cyclosporine, anti-cytokine therapy, or chemotherapy \[[@pone.0219970.ref034]\].

Comparison of clinical and laboratory features between patients with MAS-associated KFD, AOSD, and SLE showed that they had different characteristics. Notably, a higher proportion of patients with KFD were able to stop steroids within 3 months compared to patients with SLE or AOSD. Additionally, fewer immunosuppressive agents were administered to patients with MAS and KFD than to patients with MAS and AOSD or SLE. Hence, the clinical course of MAS-associated KFD is milder than MAS with SLE or AOSD, suggesting that the treatment of MAS should be tailored to the underlying diseases.

In our data, 50% (12/24) of KFD patients with MAS received bone marrow evaluation and only 16.7% (2/12) patients were found to have hemophagocytosis. Although this is a small number of patients in a retrospective study, the incidence of hemophagocytosis in our KFD patients were lower than other studies with autoimmune diseases. In a recent review paper of MAS with autoimmune diseases, 42%-100% were positive for bone marrow hemophagocytosis in patients with SLE, Kawasaki disease, and sJIA \[[@pone.0219970.ref035]\]. In our recent MAS study with AOSD patients, 50% was positive for hemophagocytosis in bone marrow evaluation \[[@pone.0219970.ref026]\]. It is possible that our KFD patients might have received bone marrow biopsy in the early course which often makes the result negative \[[@pone.0219970.ref021]\]. It is also possible that macrophage activation in lymph nodes might be enough to drive MAS in KFD. Although in the autoimmune area, bone marrow analysis is not always required for diagnosis of MAS, it is of interest to validate our finding in future studies.

The strength of this study is that, to our knowledge, it is the first study to investigate the incidence and clinical outcomes of MAS in patients with KFD. We only included patients whose diagnoses were confirmed pathologically, further validating our results. Since KFD is prevalent in young Asian women, we have a large population of patients with KFD at our institution, enabling recruitment of a statistically significant number of patients for this study. However, our study also has several limitations. First, it is a retrospective study, and the data were collected by reviewing the hospital's medical records. Second, there were patients who did not have ferritin, fibrinogen, and triglyceride level results; this might have influenced patient selection and classification resulting in selection bias because clinically severe patients may undergo more blood tests. Therefore, the incidence of MAS in our study might be relevant in patients with KFD and severe clinical or laboratory features. Third, data regarding pro-inflammatory cytokines (TNF-α, interferon-γ, IL-1, IL-6, and soluble CD163) associated with MAS were not obtainable because the following tests were not available in our hospitals \[[@pone.0219970.ref036], [@pone.0219970.ref037]\]. Because these cytokines are known to play an important role in the pathogenesis of MAS \[[@pone.0219970.ref030], [@pone.0219970.ref031]\], assessment of such tests in future studies would provide additional significance. Fourth, because the 2016 classification criteria for MAS have only been validated in patients with sJIA, caution should be made when applying the criteria to non-sJIA diseases. HLH-2004 criteria may be more suitable for non-sJIA diseases. Because a majority of patients had not undergone tests of bone marrow study, natural killer cell activity, and soluble CD25, we could not validate our finding using HLH-2004 criteria.

In conclusion, our findings suggest that the application of the 2016 EULAR/ACR/PRINTO criteria for MAS in hospitalised patients with KFD can be useful in detecting MAS. In addition, although the clinical and laboratory findings were different based on the underlying autoimmune disease, the presence of MAS based on the 2016 EULAR/ACR/PRINTO criteria was associated with adverse patient prognosis. Especially older patients with KFD who presents with features of MAS may be associated with a high mortality rate and may need special attention. Therefore, monitoring patients with KFD according to the 2016 criteria for MAS might aid in predicting patient prognosis and the stratification of high-risk patients.
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###### Flowchart for patient selection.

The flowchart for patient inclusion.
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###### HScore and the probability of having hemophagocytic syndrome among patients with MAS in KFD, AOSD, and SLE.

Comparison of HScore (A) and the probability of having hemophagocytic syndrome (B) in patients with MAS and KFD, AOSD, or SLE. HScore; hemophagocytic syndrome score; MAS, macrophage activation syndrome; KFD, Kikuchi-Fujimoto disease; AOSD, adult onset Still's disease; SLE, systemic lupus erythematosus.
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###### Kaplan-Meier survival curve of 90-day mortality among patients with MAS in KFD, AOSD, and SLE.

Comparison of survival probability among patients with MAS in KFD, AOSD, and SLE. MAS, macrophage activation syndrome; KFD, Kikuchi-Fujimoto disease; AOSD, adult onset Still's disease; SLE, systemic lupus erythematosus.
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###### The clinical data of study patients.

The raw data of this study are shown in the excel file.

(XLSX)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
